Related Experiment Video
Updated: Jun 13, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Cangrelor in Patients Undergoing Percutaneous Coronary Intervention After Out-of-Hospital Cardiac Arrest
Marco Ferlini1, Luca Raone1,2, Sara Bendotti1,3
1Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
Insights
Cangrelor use in out-of-hospital cardiac arrest survivors undergoing percutaneous coronary intervention improved survival but increased bleeding. Further research is needed to confirm net clinical benefit in this high-risk population.
Area of Science:
- Cardiology
- Interventional Cardiology
- Critical Care Medicine
Background:
- Cangrelor offers rapid platelet inhibition, a critical factor for patients with out-of-hospital cardiac arrest (OHCA) undergoing percutaneous coronary intervention (PCI).
- Limited clinical data exist regarding cangrelor's efficacy and safety specifically in the OHCA population post-PCI.
- This study addresses the gap by examining in-hospital outcomes associated with cangrelor use in OHCA survivors.
Purpose of the Study:
- To investigate the in-hospital outcomes of cangrelor administration in patients who experienced OHCA and subsequently underwent PCI.
- To compare survival rates and bleeding complications between OHCA patients treated with cangrelor versus those who were not.
- To assess the association between cangrelor use and adjusted in-hospital survival and major bleeding events.
Main Methods:
- A prospective, observational study design was employed, utilizing data from the Lombardia CARe Registry (January 2015-December 2022).
- OHCA patients who underwent PCI across seven centers in Northern Italy were included.
- Propensity score matching was used to compare outcomes between cangrelor recipients and non-recipients, with logistic regression analyzing discharge outcomes.
Main Results:
- Out of 612 OHCA patients, 414 underwent PCI; 34 (8.2%) received cangrelor.
- Cangrelor use was associated with significantly higher in-hospital survival at discharge (82.4% vs. 65.3%, p=0.043), even after propensity score matching (OR 2.07).
- Major bleeding rates were substantially higher in the cangrelor group (OR 7.0, p < 0.001), despite adjustment for baseline bleeding risk.
Conclusions:
- In OHCA patients undergoing PCI, cangrelor administration was linked to improved in-hospital survival.
- However, cangrelor use was also associated with a significant increase in major bleeding events.
- The findings suggest a potential trade-off between survival benefits and bleeding risks, warranting careful consideration for net clinical benefit.
Abstract:
Background: Cangrelor provides rapid platelet inhibition, making it a potential option for out-of-hospital cardiac arrest (OHCA) survivors undergoing percutaneous coronary intervention (PCI). However, clinical data on its use after OHCA are limited. This study investigates in-hospital outcomes of cangrelor use in this population. Methods: We conducted a prospective, observational study involving OHCA patients from the Lombardia CARe Registry (January 2015-December 2022) who underwent PCI in seven centers in Northern Italy. Propensity score (PS) matching compared patients who received cangrelor to those who did not. Logistic regression tested associations between cangrelor and discharge outcomes. Results: Of 612 OHCA patients admitted, 414 (67.4%) underwent PCI with known antithrombotic therapy, of whom 34 (8.2%) received cangrelor. Radial access was more common in the cangrelor group, which also had a higher troponin peak and a final TIMI flow grade of 3. Survival at discharge was 82.4% in the cangrelor group, compared to 65.3% in the no-cangrelor group (p = 0.043). Univariable logistic regression showed that cangrelor use was associated with higher survival at discharge (OR 2.5; 95% CI: 1.1-6.1, p = 0.049). After multiple PS matchings, cangrelor remained associated with better survival (OR 2.07; 95% CI: 1.16-2.98). Major bleeding rates were higher in the cangrelor group, even after adjusting for baseline bleeding risk (OR: 7.0; 95% CI: 2.9-17.0; p < 0.001). Conclusions: In OHCA patients undergoing PCI, cangrelor use was linked to improved in-hospital survival but higher major bleeding, suggesting a potential net clinical benefit.
More Related Videos
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:20Angina V: Nursing Management
01:21Cardiopulmonary Resuscitation I: Adult
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management